Back to today’s briefing

Story perspectives

Regeneron Acquires 23andMe Amid Genetic Privacy Concerns

5/25/2025

41 5

Summary

Story summary

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million, aiming to harness its genetic data for groundbreaking drug research. This move comes as bipartisan senators push the Don’t Sell My DNA Act to safeguard genetic privacy following 23andMe's bankruptcy. The deal is anticipated to close in Q3 2025, highlighting the urgent need for data protection.

1 of 1

Story summary

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million, aiming to harness its genetic data for groundbreaking drug research. This move comes as bipartisan senators push the Don’t Sell My DNA Act to safeguard genetic privacy following 23andMe's bankruptcy. The deal is anticipated to close in Q3 2025, highlighting the urgent need for data protection.